Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

29 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer

ABSTRACT: Anaysis of the response to different therapeutic agents at the transcriptional level. The design of the experiment allows to determine how the comnination target therapy (Rapamycin + PD0325901) treatment shifted the transcriptome towards a less aggressive or even a wild type phenotype. It also allows exploring the molecular changes involved in the transition from a non metastatic to a metastatic prostate cancer mouse model. Total RNA obtained form vehicle treated Nkx3.1CE2/+; Ptenf/f; BrafCA/+ (n=3), combinatorial Rapamycin and PD0325901 treated Nkx3.1CE2/+; Ptenf/f; BrafCA/+ (n=3) and vehicle treated intact Nkx3.1CE2/+; Ptenf/f (n = 6) prostate. Please contact Cory Abate-Shen (cabateshen@columbia.edu) and Jingqiang Wang (jw2639@columbia.edu) for questions about the submission.

ORGANISM(S): Mus musculus

SUBMITTER: Antonina Mitrofanova

PROVIDER: E-GEOD-39190 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer

Project description:Anaysis of the response to different therapeutic agents at the transcriptional level. The design of the experiment allows to determine how the comnination target therapy (Rapamycin + PD0325901) treatment shifted the transcriptome towards a less aggressive or even a wild type phenotype. It also allows exploring the molecular changes involved in the transition from a non metastatic to a metastatic prostate cancer mouse model.

2012-07-19 | GSE39190 | GEO

Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model

Project description:Analyses of differential gene expression analyses from intact versus castrated Nkx3.1CE2/+ or Nkx3.1CE2/+; Ptenf/f mice Total RNA isolated form phenotypically wild-type (intact) Nkx3.1CE2/+ (n = 3), intact Nkx3.1CE2/+; Ptenf/f (n = 6), and castrated Nkx3.1CE2/+; Ptenf/f (n = 6) prostate. Please contact Cory Abate-Shen (cabateshen@columbia.edu) for questions about the submission.

2012-07-03 | E-GEOD-39054 | biostudies-arrayexpress

FoxO3a drives a regulatory network associated with therapeutic response in metastatic prostate cancer

Project description:Anaysis of the response to different therapeutic agents at the transcriptional level. The design of the experiment allows to determine how the combination target therapy (Rapamycin + PD0325901) treatment shifts the transcriptome towards a less aggressive or even a wild type phenotype more efficiently than conventional chemotherapy (Docetaxel). It also allows exploring the molecular chages involved in the transition from a non metastatic to a metastatic prostate cancer mouse model.

2022-10-04 | GSE32053 | GEO

Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models (I)

2015-09-17 | GSE69211 | GEO

Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models (I)

Project description:Analysis of the transcriptome of mouse models of prostate cancer after treatment with rapamycin and PD0325901 combination therapy or standard of care docetaxel. The Nkx3.1CreERT2/+; Ptenflox/flox; KrasLSL-G12D/+ (NPK mice) was used in this study. Two months after tumor induction, mice were randomly assigned to vehicle (Veh) or treatments groups, such as rapamycin and PD0325901 (RAPPD) or docetaxel (Docetaxel). For the treatment groups mice were administered rapamycin (10 mg/kg) and PD0325901 (10 mg/kg) or docetaxel (10 mg/kg) for 5 days (SHORT) or for 1 month (LONG). At the end of the treatment, mice were euthanized, tumors harvested and snap frozen for subsequent molecular analysis. Total RNA obtained from prostate tumors/tissues. Prostate tumors/tissues were harvested and processed for RNA isolation and transcriptome analysis using the MagMAX RNA isolation kit (Ambion). Total RNA was amplified and labelled for subsequent microarrays hybridization using the Illumina TotalPrep RNA Amplification Kit.

2015-09-17 | E-GEOD-69211 | biostudies-arrayexpress

Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models (II)

Project description:Analysis of the transcriptome of allografted mouse tumors after treatment with rapamycin and PD0325901. Nkx3.1CreERT2/+; Ptenflox/flox; KrasLSL-G12D/+ (NPK mice) were induced and their tumors removed to generate allograft lines by implanting a 1.5 mm3 tumor fragment in the subcutaneous space of athymic nude mice. Allografted NPK tumors were allowed to grow until they reached a volume of 1 cm3, at which moment they were randomly assigned to either vehicle (Veh) or combination therapy using rapamycin and PD0325901 (RAPPD). Allografted mice were administered rapamycin (10 mg/kg) and PD0325901 (10 mg/kg) during five consecutive days (Allo SHORT). Mice were euthanized in the fifth day 6 hours after having received the last treatment and the tumors were harvested and snap frozen for subsequent molecular analysis. Total RNA obtained from prostate tumors/tissues. Prostate tumors/tissues were harvested and processed for RNA isolation and transcriptome analysis using the MagMAX RNA isolation kit (Ambion). Total RNA was amplified and labelled for subsequent microarrays hybridization using the Illumina TotalPrep RNA Amplification Kit.

2015-09-17 | E-GEOD-69213 | biostudies-arrayexpress

Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models (II)

2015-09-17 | GSE69213 | GEO

A pivotal role of SRC-2 in Metastatic and Castration Resistant Prostate Cancer

Project description:SRC-2 is frequently amplified or overexpressed in metastatic prostate cancer patients. In this study, we used genetically engineered mice, overexpressing SRC-2 specifically in the prostate epithelium as a mouse model to examine the role of SRC-2 in prostate tumorigenesis. Over-expression of SRC-2 in PTEN heterozygous mice accelerates PTEN mutation induced tumor progression and develops a metastasis-prone cancer. We used microarrays to examine the molecular profile of prostate-specific SRC-2 overexpression adult dorsal-lateral prostate in comparison with that of control PTENF/+ heterozygous deletion mice.

2014-06-30 | GSE54678 | GEO

Toxicoproteomics of environmental mixtures in prostate diseases

Project description:These data are from the following 2 experiments: 1. normal prostate stromal cells (BHPRS1) treated with either 0.1 uM mono(2-ethylhexyl) phthalate (MEHP), 3 uM perfluorooctanesulfonic acid (PFOS), the mixture of MEHP+PFOS, or DMSO vehicle (0.06% v/v); n=3 each 2. metastatic prostate epithelial cells (MT10) treated with 50 uM mono(2-ethylhexyl) phthalate (MEHP) or DMSO vehicle (0.06% v/v); n=4 each

2024-05-21 | PXD014428 | Pride

A pivotal role of SRC-2 in Metastatic and Castration Resistant Prostate Cancer

2014-06-30 | E-GEOD-54678 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data